BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Jun 13th, 2024

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical technology company’s stock.

Other research analysts also recently issued reports about the company. Benchmark reiterated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Tuesday, May 14th. Maxim Group downgraded BIOLASE from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 24th.

Read Our Latest Research Report on BIOL

BIOLASE Stock Down 4.5 %

NASDAQ:BIOL opened at $0.15 on Thursday. BIOLASE has a 1 year low of $0.13 and a 1 year high of $10.31. The stock has a 50-day moving average price of $0.16 and a two-hundred day moving average price of $0.49. The stock has a market cap of $4.98 million, a price-to-earnings ratio of -0.01 and a beta of 0.74. The company has a current ratio of 1.17, a quick ratio of 0.64 and a debt-to-equity ratio of 34.06.

BIOLASE (NASDAQ:BIOL – Get Free Report) last posted its earnings results on Monday, May 13th. The medical technology company reported ($0.36) earnings per share (EPS) for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%. The business had revenue of $10.13 million for the quarter.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.79% of the company’s stock.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.